Actelion (OTCMKTS:ALIOF) and Aurora Cannabis (NYSE:ACB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.
This is a breakdown of current recommendations and price targets for Actelion and Aurora Cannabis, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aurora Cannabis has a consensus target price of $9.50, indicating a potential upside of 34.56%.
This table compares Actelion and Aurora Cannabis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
2.6% of Aurora Cannabis shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Actelion and Aurora Cannabis’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Actelion||$2.46 billion||0.00||$707.04 million||N/A||N/A|
|Aurora Cannabis||$43.49 million||162.11||$56.66 million||N/A||N/A|
Actelion has higher revenue and earnings than Aurora Cannabis.
Actelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.
About Aurora Cannabis
Aurora Cannabis Inc. produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company's products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products. It also operates CanvasRX, a network of cannabis counseling and outreach centers; and provides cannabis analytical product testing services. The company has operations in 19 countries across five continents. Aurora Cannabis Inc. has collaboration agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart for the distribution, sale, and marketing of medical cannabis products through their respective networks of pharmacies. The company has a strategic agreements with Hempco Food and Fiber Inc.; CTT Pharmaceuticals Inc.; Choom Holdings Inc.; Capcium Inc.; The Green Organic Dutchman Holdings Ltd.; Société des Alcools du Québec; Alcanna; Radient Technologies; Micron Waste; Wagner Dimas; Evio; and Cann Group Limited. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Receive News & Ratings for Actelion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actelion and related companies with MarketBeat.com's FREE daily email newsletter.